Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Epacadostat and Pembrolizumab in Patients With Imatinib Refractory Advanced Gastrointestinal Stromal Tumors

NCT03291054 is registered in ClinicalTrials.gov with Columbia University as lead sponsor.

NCT NCT03291054
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03291054 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Epacadostat and Pembrolizumab in Patients With Imatinib Refractory Advanced Gastrointestinal Stromal Tumors
Lead sponsor
Columbia University
Phase
Phase 2
Overall status
Terminated
Start date
February 28, 2018
Completion date
August 19, 2020
Enrollment
1 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal stromal tumors